Results 261 to 270 of about 46,055 (312)
Some of the next articles are maybe not open access.
Conjugated Heptavalent Pneumococcal Vaccine
The Annals of Pharmacotherapy, 2002OBJECTIVE: To review the immunogenicity, efficacy, and safety of the heptavalent conjugated pneumococcal vaccine (PCV7). DATA SOURCES: A MEDLINE search (1993–August 2001) of research limited to humans published in the English language was conducted. STUDY SELECTION: Findings from randomized, controlled, multicenter trials were reviewed.
Vinita B, Pai +2 more
openaire +2 more sources
Innovative Vaccine Strategy: Self-Adjuvanting Conjugate Vaccines
2023Self-adjuvanting vaccines, covalent conjugates between antigens and adjuvants, are chemically well-defined compared with conventional vaccines formulated through mixing antigens with adjuvants. Innate immune receptor ligands effectively induce acquired immunity through the activation of innate immunity, thereby enhancing host immune responses.
Yoshiyuki, Manabe, Koichi, Fukase
openaire +2 more sources
Pneumococcal Conjugate Vaccines
1995The development of multivalent pneumococcal vaccines for the prevention of both systemic and noninvasive pneumococcal diseases in infants, older adults, and immunecompromised individuals has gained increasing importance over the last decade. The rising cost of medical care has renewed interest in prevention instead of cure for a disease and in many ...
openaire +2 more sources
Revue medicale de Bruxelles, 2002
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire +2 more sources
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire +2 more sources
PolysaccharicbConjugate Vaccines
2003It was recognized early this century that small molecules, called haptens, can be made immunogenic after conjugation to carrier proteins (1), This principle was thereafter applied successfully to improve the rmmunogenicity of (poly)saccharides (2, 3). We now know that the carrier proteins ensure the involvement of T-helper lymphocytes in the activation
C C, Peeters +6 more
openaire +2 more sources
Revue medicale de Bruxelles, 2002
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire +1 more source
Conjugate vaccines extend the vaccinal prevention for children to more diseases. Conjugating the capsular polysaccharide to a carrier protein transforms a T-independent antigen in a T-dependent, allowing protection of the children (before 2 years of age) against Haemophilus influenzae type b, meningococcal C and pneumococcal infections.
B, Swennen, J, Sternon
openaire +1 more source
Meningococcal tetravalent conjugate vaccine
Expert Opinion on Biological Therapy, 2008Neisseria meningitidis is a leading cause of meningitis and sepsis worldwide. Since 1981, a tetravalent meningococcal polysaccharide vaccine has been available in the US but it has been limited to high-risk patients and outbreak settings. In 2005, a tetravalent polysaccharide meningococcal conjugate vaccine (MCV4) was licensed for routine use in the US.
openaire +2 more sources
Pneumococcal conjugate vaccines
The Pediatric Infectious Disease Journal, 1999J, Eskola, M, Anttila
openaire +4 more sources
Therapie, 2005
Encapsulated bacterial pathogens (e.g. Haemophilus influenzae type b [Hib], Neisseria meningitidis, or Streptococcus pneumoniae) target infants and young children who have lost any protective anti-capsular antibodies supplied maternally and whose immune systems are ineffective against T-independent antigens such as the polysaccharides of the capsule ...
openaire +1 more source
Encapsulated bacterial pathogens (e.g. Haemophilus influenzae type b [Hib], Neisseria meningitidis, or Streptococcus pneumoniae) target infants and young children who have lost any protective anti-capsular antibodies supplied maternally and whose immune systems are ineffective against T-independent antigens such as the polysaccharides of the capsule ...
openaire +1 more source